Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748774 · ClinicalTrials.gov registry record
Brain Tumor Patient-Caregiver Congruence, MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)
A clinical trial of Brain Tumor, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 115
- Enrollment target
- 1
- Study location
NCT00748774 is a study of Brain Tumor that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 115 participants, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00748774, a study of Brain Tumor, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to compare patient ratings of how severe their own symptoms may be, with their caregivers' ratings of how severe they think the patients' symptoms may be. This will be compared using a questionnaire that is given to patients with brain tumors and their caregivers. Researchers will also study any effects that these patients' neurocognitive function may have on these patients' and their caregivers' ratings of how severe the brain cancer symptoms may be.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaire
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748774
The ClinicalTrials.gov registry entry for NCT00748774 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (59% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which Questionnaire is the first listed.
NCT00748774 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00748774 about?
NCT00748774 is a clinical study titled "Brain Tumor Patient-Caregiver Congruence, MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)". The goal of this study is to compare patient ratings of how severe their own symptoms may be, with their caregivers' ratings of how severe they think the patients' symptoms may be. This will be compared using a questionnaire that is given to patients with brain tumors and their caregivers. Research...
What is the current status of trial NCT00748774?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2008-05. Estimated completion is 2014-09.
What conditions does trial NCT00748774 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT00748774?
The interventions under investigation include: Questionnaire (BEHAVIORAL).
Who is sponsoring clinical trial NCT00748774?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00748774 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.